Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $37.00.
ODTX has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Weiss Ratings assumed coverage on Odyssey Therapeutics in a research report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Raymond James Financial began coverage on shares of Odyssey Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $42.00 price target on the stock. HC Wainwright began coverage on shares of Odyssey Therapeutics in a research report on Thursday, August 27th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a report on Thursday, June 18th.
Check Out Our Latest Stock Report on ODTX
Institutional Investors Weigh In On Odyssey Therapeutics
Odyssey Therapeutics Price Performance
NASDAQ ODTX opened at $19.00 on Monday. The firm has a market cap of $913.14 million and a price-to-earnings ratio of -2.81. The firm has a 50-day simple moving average of $22.76. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05.
Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. Equities research analysts expect that Odyssey Therapeutics will post -6.20 earnings per share for the current year.
Odyssey Therapeutics Company Profile
Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.
Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.
Featured Articles
- Five stocks we like better than Odyssey Therapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
